Correspondence 0001193125-23-183778 from Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Date: July 7, 2023 · CIK: 0001610618 · Accession: 0001193125-23-183778
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36912
Letter
July 7, 2023
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Vanessa Robertson
Daniel Gordon
Re: Cidara Therapeutics, Inc.
Form 10-K for the fiscal year ended December 31, 2022
Filed March 23, 2023
File No. 001-36912
Ladies and Gentlemen:
We are in receipt of the comment letter, dated June 26, 2023, received by Cidara Therapeutics, Inc. (the “Company,” “we,” “our” or similar terminology) on June 27, 2023, from the staff (the “Staff”) of the Securities and Exchange Commission (the “SEC”) regarding the above captioned filing on Form 10-K filed on March 23, 2023 (the “Form 10-K”). Below is the response of the Company to the Staff’s comments.
For the Staff’s convenience, we have incorporated the Staff’s comment into this response letter in italics. The Company acknowledges that it is responsible for the adequacy and accuracy of the disclosure in the Form 10-K.
Form 10-K for the fiscal year ended December 31, 2022
Notes to Consolidated Financial Statements
8. Significant Agreements and Contracts, page 95
1. On page 3 of your response you state that you recognized revenue of $37.5 million from payments received in 2022 related to upfront and milestone payments. Please provide us with a reconciliation of how the $37.5 million ties to the revenue recognized in 2022 disclosed in the table on page 2 of your response. Also please clarify how the $19.2 million recognized for R&D services and clinical supplies services ties to the table on page 2 of the response.
Company Response
In 2022, we received a total of $47.9 million in upfront and milestone payments consisting of: $11.1 million for a Mundipharma milestone (as disclosed on page 96 of our Form 10-K), $3.0 million for a Janssen milestone (as disclosed on page 98 of our Form 10-K), $30.0 million for the Melinta upfront payment (as disclosed on page 99 of our Form 10-K), and $3.7 million upfront for commercial supplies. We recognized revenue of $37.5 million from those payments in 2022 related to performance obligations satisfied, as follows: $8.8 million of the Mundipharma milestone ($3.3 million allocated to the license, $5.1 million allocated to R&D services, and $0.5 million allocated to clinical supply services), $1.9 million of the Janssen milestone ($0.8 million allocated to the license, $0.7 million allocated to R&D services, and $0.4 million allocated to clinical supply services), and $26.7 million of the Melinta upfront payment ($25.9 million allocated to the license and $0.8 million allocated to R&D services). We also received reimbursement payments from Mundipharma and Janssen of $19.2 million in 2022 for R&D services and clinical supply services performed in that same period, which were recognized as revenue in 2022 related to performance obligations satisfied as follows: $1.1 million for Mundipharma ($0.5 million allocated to clinical drug supply and $0.6 million allocated to R&D services) and $18.1 million for Janssen ($14.8 million allocated to R&D services and $3.3 million allocated to clinical supply services). In addition, we recognized $7.6 million of revenue for performance obligations satisfied in 2022 related to upfront and milestone payments received before January 1, 2022, as follows: $4.4 million for Mundipharma ($4.0 million allocated to R&D services and $0.4 million allocated to clinical supply services) and $3.3 million for Janssen (allocated to R&D services). Further detail reconciling our revenue recognition for 2022 is provided in the tables below.
Table 1
Year Ended December 31, 2022
(in thousands)
Mundipharma
Janssen
Melinta
Revenue from Collaboration and License Agreements:
Related to upfront and milestone payments received after January 1, 2022:
License of Intellectual Property – upon transfer of license1
$ —
$ —
$ 25,885
License of Intellectual Property – upon milestone achieved1
3,252
A
—
Research and Development Services2
5,060
Clinical Supply Services2
—
Total revenue recognized from upfront and milestone payments received after January 1, 2022:
8,787
1,893
26,668
Related to reimbursement payments received after January 1, 2022:
Clinical Drug Supply1
—
—
Research and Development Services2
14,816
Clinical Supply Services2
—
3,282
—
Total revenue recognized from reimbursement payments received after January 1, 2022:
1,061
18,098
Related to upfront and milestone payments received before January 1, 2022:
Research and Development Services2
3,958
3,308
—
Clinical Supply Services2
—
Total revenue recognized from upfront and milestone payments received before January 1, 2022:
4,408
3,345
—
Total Revenue from Collaboration and License Agreements
$ 14,256
$ 23,336
$ 26,696
Revenue is recognized at a point in time.
Revenue is recognized over time.
A Includes an adjustment of $0.2 million to reduce the revenue recognized in 2022 for the license delivered and payment received before January 1, 2022 which was deemed to be not material.
Table 2
Year Ended December 31, 2022
(in thousands)
Mundipharma
Janssen
Melinta
Total
Revenue from Collaboration and License Agreements:
Total revenue recognized from upfront and milestone payments received after January 1,
$ 8,787
$ 1,893 A
$ 26,668
$ 37,348 A
Total revenue recognized from reimbursement payments received after January 1, 2022
$ 1,061
$ 18,098
$
$ 19,187
Total revenue recognized from upfront and milestone payments received before January 1,
$ 4,408
$ 3,345
$ —
$ 7,753
Total Revenue from Collaboration and License Agreements
$ 14,256
$ 23,336
$ 26,696
$ 64,288
A Includes an adjustment of $0.2 million to reduce the revenue recognized in 2022 for the license delivered and payment received before January 1, 2022 which was deemed to be not material.
Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any questions or further comments regarding this response letter to Phillip S. McGill of Cooley LLP at (858) 550-6193. Thank you.
Sincerely,
By:
/s/ Preetam Shah
Show Raw Text
CORRESP 1 filename1.htm CORRESP July 7, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Vanessa Robertson Daniel Gordon Re: Cidara Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 23, 2023 File No. 001-36912 Ladies and Gentlemen: We are in receipt of the comment letter, dated June 26, 2023, received by Cidara Therapeutics, Inc. (the “Company,” “we,” “our” or similar terminology) on June 27, 2023, from the staff (the “Staff”) of the Securities and Exchange Commission (the “SEC”) regarding the above captioned filing on Form 10-K filed on March 23, 2023 (the “Form 10-K”). Below is the response of the Company to the Staff’s comments. For the Staff’s convenience, we have incorporated the Staff’s comment into this response letter in italics. The Company acknowledges that it is responsible for the adequacy and accuracy of the disclosure in the Form 10-K. Form 10-K for the fiscal year ended December 31, 2022 Notes to Consolidated Financial Statements 8. Significant Agreements and Contracts, page 95 1. On page 3 of your response you state that you recognized revenue of $37.5 million from payments received in 2022 related to upfront and milestone payments. Please provide us with a reconciliation of how the $37.5 million ties to the revenue recognized in 2022 disclosed in the table on page 2 of your response. Also please clarify how the $19.2 million recognized for R&D services and clinical supplies services ties to the table on page 2 of the response. Company Response In 2022, we received a total of $47.9 million in upfront and milestone payments consisting of: $11.1 million for a Mundipharma milestone (as disclosed on page 96 of our Form 10-K), $3.0 million for a Janssen milestone (as disclosed on page 98 of our Form 10-K), $30.0 million for the Melinta upfront payment (as disclosed on page 99 of our Form 10-K), and $3.7 million upfront for commercial supplies. We recognized revenue of $37.5 million from those payments in 2022 related to performance obligations satisfied, as follows: $8.8 million of the Mundipharma milestone ($3.3 million allocated to the license, $5.1 million allocated to R&D services, and $0.5 million allocated to clinical supply services), $1.9 million of the Janssen milestone ($0.8 million allocated to the license, $0.7 million allocated to R&D services, and $0.4 million allocated to clinical supply services), and $26.7 million of the Melinta upfront payment ($25.9 million allocated to the license and $0.8 million allocated to R&D services). We also received reimbursement payments from Mundipharma and Janssen of $19.2 million in 2022 for R&D services and clinical supply services performed in that same period, which were recognized as revenue in 2022 related to performance obligations satisfied as follows: $1.1 million for Mundipharma ($0.5 million allocated to clinical drug supply and $0.6 million allocated to R&D services) and $18.1 million for Janssen ($14.8 million allocated to R&D services and $3.3 million allocated to clinical supply services). In addition, we recognized $7.6 million of revenue for performance obligations satisfied in 2022 related to upfront and milestone payments received before January 1, 2022, as follows: $4.4 million for Mundipharma ($4.0 million allocated to R&D services and $0.4 million allocated to clinical supply services) and $3.3 million for Janssen (allocated to R&D services). Further detail reconciling our revenue recognition for 2022 is provided in the tables below. Table 1 Year Ended December 31, 2022 (in thousands) Mundipharma Janssen Melinta Revenue from Collaboration and License Agreements: Related to upfront and milestone payments received after January 1, 2022: License of Intellectual Property – upon transfer of license1 $ — $ — $ 25,885 License of Intellectual Property – upon milestone achieved1 3,252 816 A — Research and Development Services2 5,060 690 783 Clinical Supply Services2 475 387 — Total revenue recognized from upfront and milestone payments received after January 1, 2022: 8,787 1,893 26,668 Related to reimbursement payments received after January 1, 2022: Clinical Drug Supply1 484 — — Research and Development Services2 577 14,816 28 Clinical Supply Services2 — 3,282 — Total revenue recognized from reimbursement payments received after January 1, 2022: 1,061 18,098 28 Related to upfront and milestone payments received before January 1, 2022: Research and Development Services2 3,958 3,308 — Clinical Supply Services2 450 37 — Total revenue recognized from upfront and milestone payments received before January 1, 2022: 4,408 3,345 — Total Revenue from Collaboration and License Agreements $ 14,256 $ 23,336 $ 26,696 1 Revenue is recognized at a point in time. 2 Revenue is recognized over time. A Includes an adjustment of $0.2 million to reduce the revenue recognized in 2022 for the license delivered and payment received before January 1, 2022 which was deemed to be not material. Table 2 Year Ended December 31, 2022 (in thousands) Mundipharma Janssen Melinta Total Revenue from Collaboration and License Agreements: Total revenue recognized from upfront and milestone payments received after January 1, 2022 $ 8,787 $ 1,893 A $ 26,668 $ 37,348 A Total revenue recognized from reimbursement payments received after January 1, 2022 $ 1,061 $ 18,098 $ 28 $ 19,187 Total revenue recognized from upfront and milestone payments received before January 1, 2022 $ 4,408 $ 3,345 $ — $ 7,753 Total Revenue from Collaboration and License Agreements $ 14,256 $ 23,336 $ 26,696 $ 64,288 A Includes an adjustment of $0.2 million to reduce the revenue recognized in 2022 for the license delivered and payment received before January 1, 2022 which was deemed to be not material. Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any questions or further comments regarding this response letter to Phillip S. McGill of Cooley LLP at (858) 550-6193. Thank you. Sincerely, By: /s/ Preetam Shah Preetam Shah Chief Financial Officer and Chief Business Officer cc: Jeffrey Stein, Ph.D., Cidara Therapeutics, Inc. Shane Ward, Cidara Therapeutics, Inc. Charles J. Bair, Cooley LLP Phillip S. McGill, Cooley LLP